What is IBIO's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.05B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for IBIO?

P/E (TTM) is n/a and 52-week range is $0.78 to $3.82 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s IBIO figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for IBIO?

The company profile lists revenue (TTM) near $35K, net income (TTM) near $-106M, EPS (TTM) near $-0.54 when available from the market-data feed. Figures are informational and may lag live markets.

Where is iBio Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in San Diego, California, US, 49.7M shares outstanding, ISIN US4510337086 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

iBio Inc

$IBIO

Health Care · Biotechnology

IR Run Scenarios

$0.87

-5.33%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

iBio, Inc. is an AI-driven innovator that develops next-generation biopharmaceuticals using computational biology and 3D-modeling of subdominant and conformational epitopes, prospectively enabling the discovery of new antibody treatments for hard to target cancers, and other diseases. The company is headquartered in San Diego, California and currently employs 20 full-time employees. The company went IPO on 2008-08-18. By combining proprietary 3D modeling with drug discovery platforms, it is creating a pipeline of antibody treatments to address significant unmet medical needs. Its proprietary StableHu technology is instrumental in this optimization process. StableHu is an AI- powered tool designed to predict a library of antibodies with fully human CDR variants based on an input antibody. The company has a pipeline of pre-clinical programs with differentiated profiles and high potential impact, including IBIO-101, its second-generation anti-CD25 monoclonal antibody, a TROP-2 x CD3 bispecific antibody, an antibody that binds to a non-shed, non-glycosylated region of MUC16, an antibody that binds to an epitope on EGFRvIII without binding wildtype EGFR, and an anti-CCR8 antibody.

Employees

Website

ibioinc.com/

IPO

2008-08-18

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)